MX2021014158A - Uso de cannabidiol en el tratamiento de espasmos epilepticos. - Google Patents
Uso de cannabidiol en el tratamiento de espasmos epilepticos.Info
- Publication number
- MX2021014158A MX2021014158A MX2021014158A MX2021014158A MX2021014158A MX 2021014158 A MX2021014158 A MX 2021014158A MX 2021014158 A MX2021014158 A MX 2021014158A MX 2021014158 A MX2021014158 A MX 2021014158A MX 2021014158 A MX2021014158 A MX 2021014158A
- Authority
- MX
- Mexico
- Prior art keywords
- cbd
- equal
- less
- concentration
- epileptic
- Prior art date
Links
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 title abstract 11
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 title abstract 11
- 229950011318 cannabidiol Drugs 0.000 title abstract 11
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 title abstract 11
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 title abstract 11
- 208000005392 Spasm Diseases 0.000 title abstract 4
- 230000001037 epileptic effect Effects 0.000 title abstract 4
- 208000007101 Muscle Cramp Diseases 0.000 title abstract 3
- 239000001961 anticonvulsive agent Substances 0.000 abstract 3
- 208000026911 Tuberous sclerosis complex Diseases 0.000 abstract 2
- 229930003827 cannabinoid Natural products 0.000 abstract 2
- 239000003557 cannabinoid Substances 0.000 abstract 2
- 229940065144 cannabinoids Drugs 0.000 abstract 2
- CXOXHMZGEKVPMT-UHFFFAOYSA-N clobazam Chemical compound O=C1CC(=O)N(C)C2=CC=C(Cl)C=C2N1C1=CC=CC=C1 CXOXHMZGEKVPMT-UHFFFAOYSA-N 0.000 abstract 2
- 229960001403 clobazam Drugs 0.000 abstract 2
- CYQFCXCEBYINGO-SJORKVTESA-N (6as,10ar)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol Chemical compound C1=C(C)CC[C@@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-SJORKVTESA-N 0.000 abstract 1
- WBRXESQKGXYDOL-DLBZAZTESA-N 5-butyl-2-[(1r,6r)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]benzene-1,3-diol Chemical compound OC1=CC(CCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 WBRXESQKGXYDOL-DLBZAZTESA-N 0.000 abstract 1
- GKVOVXWEBSQJPA-UONOGXRCSA-N 5-methyl-2-[(1r,6r)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]benzene-1,3-diol Chemical compound CC(=C)[C@@H]1CCC(C)=C[C@H]1C1=C(O)C=C(C)C=C1O GKVOVXWEBSQJPA-UONOGXRCSA-N 0.000 abstract 1
- REOZWEGFPHTFEI-JKSUJKDBSA-N Cannabidivarin Chemical compound OC1=CC(CCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-JKSUJKDBSA-N 0.000 abstract 1
- 241001471082 Colocasia bobone disease-associated cytorhabdovirus Species 0.000 abstract 1
- REOZWEGFPHTFEI-UHFFFAOYSA-N cannabidivarine Natural products OC1=CC(CCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-UHFFFAOYSA-N 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
La presente invención se refiere al uso de cannabidiol (CBD) para el tratamiento de espasmos epilépticos. En particular, los espasmos epilépticos que se tratan están asociados al Complejo de Esclerosis Tuberosa (TSC). En una modalidad adicional, el espasmo epiléptico se trata con CBD en combinación con clobazam. Preferiblemente, el CBD utilizado está en la forma de un CBD purificado derivado de la botánica que comprende más de o igual al 98% (p/p) de CBD y menos de o igual al 2% (p/p) de otros cannabinoides. Los otros cannabinoides presentes son THC en una concentración de menos de o igual al 0.1% (p/p); CBD-C1 en una concentración de menos de o igual al 0.15% (p/p); CBDV en una concentración de menos de o igual al 0.8% (p/p); y CBD-C4 en una concentración de menos de o igual al 0.4% (p/p). El CBD purificado derivado de la botánica también comprende preferiblemente una mezcla tanto de trans-THC como de cis-THC. Alternativamente, se usa un CBD producido sintéticamente. Cuando el CBD se proporciona de forma concomitante con uno o más de otros fármacos antiepilépticos (AED). Cuando el CBD se proporciona de forma concomitante con uno o más de otros fármacos antiepilépticos (AED), incluido el clobazam, el CBD se puede formular para su administración por separado secuencial o simultáneamente con uno o más AED o la combinación se puede proporcionar en una sola forma de dosificación.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1907283.4A GB2584140A (en) | 2019-05-23 | 2019-05-23 | Use of cannabidiol in the treatment of epileptic spasms |
| PCT/GB2020/051185 WO2020234569A1 (en) | 2019-05-23 | 2020-05-15 | Use of cannabidiol in the treatment of epileptic spasms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021014158A true MX2021014158A (es) | 2022-01-04 |
Family
ID=67385457
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021014158A MX2021014158A (es) | 2019-05-23 | 2020-05-15 | Uso de cannabidiol en el tratamiento de espasmos epilepticos. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220257529A1 (es) |
| EP (1) | EP3972575A1 (es) |
| JP (1) | JP2022533783A (es) |
| KR (1) | KR20220011660A (es) |
| CN (1) | CN113874005A (es) |
| AU (1) | AU2020279889A1 (es) |
| BR (1) | BR112021022139A2 (es) |
| CA (1) | CA3138980A1 (es) |
| GB (1) | GB2584140A (es) |
| IL (1) | IL288195A (es) |
| MX (1) | MX2021014158A (es) |
| TW (1) | TW202110428A (es) |
| WO (1) | WO2020234569A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
| GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2569961B (en) | 2018-01-03 | 2021-12-22 | Gw Res Ltd | Pharmaceutical |
| GB201916977D0 (en) | 2019-11-21 | 2020-01-08 | Gw Res Ltd | Cannibidol-type cannabinoid compound |
| GB2597293A (en) | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain |
| GB2597283A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain |
| GB2598922A (en) | 2020-09-18 | 2022-03-23 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2531281A (en) * | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| GB2531278A (en) * | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| CA2992427A1 (en) * | 2015-04-28 | 2016-11-03 | The Regents Of The University Of California | Uses of cannabidiol for treatment of infantile spasms |
| GB2551987A (en) * | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Oral cannabinoid formulations |
| CN108236608B (zh) * | 2016-12-27 | 2020-05-08 | 汉义生物科技（北京）有限公司 | 大麻二酚与氨己烯酸的药物组合物及其用途 |
| JP2020517727A (ja) * | 2017-04-27 | 2020-06-18 | インシス・ディベロップメント・カンパニー・インコーポレイテッド | 安定なカンナビノイド製剤 |
| GB201715919D0 (en) * | 2017-09-29 | 2017-11-15 | Gw Res Ltd | use of cannabinoids in the treatment of epilepsy |
| GB201806953D0 (en) * | 2018-04-27 | 2018-06-13 | Gw Res Ltd | Cannabidiol Preparations |
-
2019
- 2019-05-23 GB GB1907283.4A patent/GB2584140A/en not_active Withdrawn
-
2020
- 2020-05-15 JP JP2021569522A patent/JP2022533783A/ja active Pending
- 2020-05-15 EP EP20728156.9A patent/EP3972575A1/en active Pending
- 2020-05-15 KR KR1020217040679A patent/KR20220011660A/ko unknown
- 2020-05-15 MX MX2021014158A patent/MX2021014158A/es unknown
- 2020-05-15 CN CN202080037941.6A patent/CN113874005A/zh active Pending
- 2020-05-15 WO PCT/GB2020/051185 patent/WO2020234569A1/en unknown
- 2020-05-15 AU AU2020279889A patent/AU2020279889A1/en not_active Abandoned
- 2020-05-15 US US17/611,824 patent/US20220257529A1/en active Pending
- 2020-05-15 BR BR112021022139A patent/BR112021022139A2/pt not_active Application Discontinuation
- 2020-05-15 CA CA3138980A patent/CA3138980A1/en active Pending
- 2020-05-22 TW TW109117081A patent/TW202110428A/zh unknown
-
2021
- 2021-11-17 IL IL288195A patent/IL288195A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20220257529A1 (en) | 2022-08-18 |
| IL288195A (en) | 2022-01-01 |
| CN113874005A (zh) | 2021-12-31 |
| EP3972575A1 (en) | 2022-03-30 |
| AU2020279889A1 (en) | 2021-11-25 |
| BR112021022139A2 (pt) | 2022-01-04 |
| TW202110428A (zh) | 2021-03-16 |
| WO2020234569A1 (en) | 2020-11-26 |
| JP2022533783A (ja) | 2022-07-25 |
| GB2584140A (en) | 2020-11-25 |
| KR20220011660A (ko) | 2022-01-28 |
| GB201907283D0 (en) | 2019-07-10 |
| CA3138980A1 (en) | 2020-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021014158A (es) | Uso de cannabidiol en el tratamiento de espasmos epilepticos. | |
| MX2021006094A (es) | Uso de cannabinoides en el tratamiento de epilepsia. | |
| MX2021009646A (es) | Uso de cannabinoides en el tratamiento de epilepsia. | |
| MX2021013285A (es) | Uso de cannabidiol en el tratamiento del complejo de esclerosis tuberosa. | |
| HRP20201506T1 (hr) | Uporaba kanabidiolne kiseline u liječenju epilepsije | |
| MX2020005719A (es) | Uso de cannabinoides en el tratamiento de epilepsia. | |
| RU2013136378A (ru) | Применение фитоканнабиноида каннабидиола(cbd) в комбинации со стандартным противоэпилептическим стедством(saed) для лечения эпилепсии | |
| SG152907A1 (en) | Combinations for the treatment of inflammatory disorders | |
| IL135335A0 (en) | Method for inhibiting or preventing hormone induced adverse effects and novel pharmaceutical compositions comprising carotenoids | |
| AR044007A1 (es) | Metodos para el tratamiento de la enfermedad de parkinson | |
| MX2020010907A (es) | Mejora de suministro de agentes activos lipofilicos a traves de la barrera hematoencefalica y metodos para tratar trastornos del sistema nervioso central. | |
| FR2949044B1 (fr) | Composition comprenant une fraction d'insaponifiable | |
| AR043188A1 (es) | Metodos y composiciones para el tratamiento de enfermedades y trastornos asociados con niveles elevados de citoquinas proinflamatorias | |
| MX2022010483A (es) | Metodos de tratamiento del complejo de esclerosis tuberosa con cannabidiol y everolimus. | |
| MX2022001337A (es) | Uso de cannabidiol en el tratamiento del sindrome de dravet. | |
| MX2022004257A (es) | Composicion farmaceutica y metodo para tratamiento de los trastornos convulsionales. | |
| WO2023088497A3 (zh) | 一种氧化氮供体型贝前列素类衍生物及其药物组合物和用途 | |
| HUP0301828A2 (hu) | Apomorfin alkalmazása nemi mżködészavar meghatározott apomorfin-plazmakoncentrációval történż kezelésre szolgáló készítmények elżállítására | |
| AR047726A1 (es) | Metodos y reactivos para el tratamiento de trastornos inflamatorios | |
| UA91028C2 (ru) | Использование лавандового масла для профилактики и лечения соматических расстройств и посттравматического стресса | |
| MY197721A (en) | Composition and uses thereof | |
| WO2006089120A3 (en) | Compositions, methods of use and preparation of 2,6-diisopropyl phenol and analogs for ischemic injury | |
| MX2022014199A (es) | Usos y formulaciones de los cannabinoides. | |
| MX2022004295A (es) | Extractos terapeuticos de cannabis. | |
| KR20230090185A (ko) | 위 점막 병변을 동반한 류마티스 관절염을 치료하는 약제학적 복합제제 |